PMID- 27314293
OWN - NLM
STAT- MEDLINE
DCOM- 20170118
LR  - 20170118
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Linking)
VI  - 17
IP  - 1
DP  - 2016 Jun 7
TI  - Osteopontin as a discriminating marker for pancreatic cancer and chronic 
      pancreatitis.
PG  - 55-65
LID - 10.3233/CBM-160617 [doi]
AB  - INTRODUCTION: We analyzed concentrations of osteopontin (OPN) in patients with 
      pancreatic ductal adenocarcinoma (PDAC) in order to determine firstly whether it 
      is useful to distinguish between PDAC patients and those with chronic 
      non-hereditary pancreatitis (CP) and type 2 diabetes mellitus (T2DM), and 
      secondly whether OPN concentrations depend on the PDAC stage. METHODS: Groups 
      consisting of 64 patients with PDAC, 71 with CP, 67 with T2DM and 48 healthy 
      controls (CON) were enrolled in the study. Controls were compared with regard to 
      levels of OPN, oxidative stress markers, conventional tumor markers and other 
      biochemical parameters. RESULTS: Levels of OPN were higher in patients with PDAC 
      compared with CP patients (P< 0.001), T2DM (P< 0.001) and CON (P< 0.001). There 
      were increased OPN levels in CP patients in comparison with T2DM (P< 0.001) and 
      CON (P< 0.001). Patients with PDAC in stage IV had higher OPN levels than PDAC 
      patients in stage III (P< 0.01). There was no difference in OPN levels of PDAC 
      patients in stage III compared to patients in stage II. CONCLUSION: Our pilot 
      study demonstrates the usefulness of estimating OPN levels to differentiate 
      between pancreatic cancer and chronic pancreatitis. Higher OPN levels over 102 
      ng/ml could be a potential diagnostic biomarker for pancreatic cancer.
FAU - Rychlikova, Jana
AU  - Rychlikova J
AD  - 4th Department of Internal Medicine, First Faculty of Medicine, Charles 
      University and General University Hospital, Prague, Czech Republic.
FAU - Vecka, Marek
AU  - Vecka M
AD  - 4th Department of Internal Medicine, First Faculty of Medicine, Charles 
      University and General University Hospital, Prague, Czech Republic.
FAU - Jachymova, Marie
AU  - Jachymova M
AD  - Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of 
      Medicine Charles University in Prague, Prague, Czech Republic.
FAU - Macasek, Jaroslav
AU  - Macasek J
AD  - 4th Department of Internal Medicine, First Faculty of Medicine, Charles 
      University and General University Hospital, Prague, Czech Republic.
FAU - Hrabak, Petr
AU  - Hrabak P
AD  - 4th Department of Internal Medicine, First Faculty of Medicine, Charles 
      University and General University Hospital, Prague, Czech Republic.
FAU - Zeman, Miroslav
AU  - Zeman M
AD  - 4th Department of Internal Medicine, First Faculty of Medicine, Charles 
      University and General University Hospital, Prague, Czech Republic.
FAU - Vavrova, Lucie
AU  - Vavrova L
AD  - 4th Department of Internal Medicine, First Faculty of Medicine, Charles 
      University and General University Hospital, Prague, Czech Republic.
FAU - Roupal, Jan
AU  - Roupal J
AD  - 3rd Department of Internal Medicine, First Faculty of Medicine Charles University 
      and General University Hospital, Prague, Czech Republic.
FAU - Krechler, Tomas
AU  - Krechler T
AD  - 4th Department of Internal Medicine, First Faculty of Medicine, Charles 
      University and General University Hospital, Prague, Czech Republic.
FAU - Ak, Ales
AU  - Ak A
AD  - 4th Department of Internal Medicine, First Faculty of Medicine, Charles 
      University and General University Hospital, Prague, Czech Republic.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (Biomarkers)
RN  - 0 (Biomarkers, Tumor)
RN  - 106441-73-0 (Osteopontin)
SB  - IM
MH  - Aged
MH  - Biomarkers
MH  - *Biomarkers, Tumor
MH  - Carcinoma, Pancreatic Ductal/blood/diagnosis
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/blood/diagnosis
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteopontin/*blood
MH  - Pancreatic Neoplasms/*blood/*diagnosis
MH  - Pancreatitis, Chronic/*blood/*diagnosis
OTO - NOTNLM
OT  - Osteopontin
OT  - chronic non-hereditary pancreatitis
OT  - pancreatic ductal adenocarcinoma
OT  - type 2 diabetes mellitus
EDAT- 2016/06/18 06:00
MHDA- 2017/01/19 06:00
CRDT- 2016/06/18 06:00
PHST- 2016/06/18 06:00 [entrez]
PHST- 2016/06/18 06:00 [pubmed]
PHST- 2017/01/19 06:00 [medline]
AID - CBM617 [pii]
AID - 10.3233/CBM-160617 [doi]
PST - ppublish
SO  - Cancer Biomark. 2016 Jun 7;17(1):55-65. doi: 10.3233/CBM-160617.